Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review

David Aristizábal-Colorado^{1

2}, David Corredor-Rengifo^{1

2}, Santiago Sierra-Castillo³, Carolina López-Corredor⁴, David-Alexander Vernaza-Trujillo^{2

5

6}, Danilo Weir-Restrepo⁷, Juan S Izquierdo-Condoy⁸, Esteban Ortiz-Prado⁸, Jorge Rico-Fontalvo^{9

10}, Juan-Esteban Gómez-Mesa^{11

12}, Alin Abreu-Lomba¹³, Wilfredo-Antonio Rivera-Martínez^{2

14}

Affiliations

¹ Internal Medicine Department, Universidad Libre, Cali, Colombia.
² Grupo Interinstitucional de Medicina Interna (GIMI1), Universidad Libre, Cali, Colombia.
³ Epidemiology Department, Universidad Centros de Estudios en Salud (CES), Medellín, Colombia.
⁴ Medicine Program, Universidad Santiago de Cali, Cali, Colombia.
⁵ Department of Public Health, Pontificia Universidad Javeriana, Cali, Colombia.
⁶ Clinical Research Center, Clínica Imbanaco, Cali, Colombia.
⁷ Internal Medicine Department, Universidad Centros de Estudios en Salud (CES), Medellin, Colombia.
⁸ One Health Research Group, Universidad de las Américas, Quito, Ecuador.
⁹ Department of Nephrology, Faculty of Medicine, Universidad Simón Bolívar, Barranquilla, Colombia.
¹⁰ Latin American Society of Nephrology and Arterial Hypertension (SLANH), Ciudad de Panama, Panama.
¹¹ Cardiology Department, Fundación Valle del Lili, Cali, Colombia.
¹² Department of Health Sciences, Universidad Icesi, Cali, Colombia.
¹³ Endocrinology Department, Clínica Imbanaco, Cali, Colombia.
¹⁴ Endocrinology Department, Universidad de Antioquia, Medellín, Colombia.

PMID: 40909226
PMCID: PMC12406488
DOI: 10.3389/fendo.2025.1663787

Published Erratum

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review

David Aristizábal-Colorado et al. Front Endocrinol (Lausanne). 2025.

. 2025 Aug 20:16:1663787.

doi: 10.3389/fendo.2025.1663787. eCollection 2025.

Authors

Affiliations

¹ Internal Medicine Department, Universidad Libre, Cali, Colombia.
² Grupo Interinstitucional de Medicina Interna (GIMI1), Universidad Libre, Cali, Colombia.
³ Epidemiology Department, Universidad Centros de Estudios en Salud (CES), Medellín, Colombia.
⁴ Medicine Program, Universidad Santiago de Cali, Cali, Colombia.
⁵ Department of Public Health, Pontificia Universidad Javeriana, Cali, Colombia.
⁶ Clinical Research Center, Clínica Imbanaco, Cali, Colombia.
⁷ Internal Medicine Department, Universidad Centros de Estudios en Salud (CES), Medellin, Colombia.
⁸ One Health Research Group, Universidad de las Américas, Quito, Ecuador.
⁹ Department of Nephrology, Faculty of Medicine, Universidad Simón Bolívar, Barranquilla, Colombia.
¹⁰ Latin American Society of Nephrology and Arterial Hypertension (SLANH), Ciudad de Panama, Panama.
¹¹ Cardiology Department, Fundación Valle del Lili, Cali, Colombia.
¹² Department of Health Sciences, Universidad Icesi, Cali, Colombia.
¹³ Endocrinology Department, Clínica Imbanaco, Cali, Colombia.
¹⁴ Endocrinology Department, Universidad de Antioquia, Medellín, Colombia.

PMID: 40909226
PMCID: PMC12406488
DOI: 10.3389/fendo.2025.1663787

Abstract

[This corrects the article DOI: 10.3389/fendo.2025.1605746.].

Keywords: GLP-1 agonists; SGLT2 inhibitors; cardiovascular outcomes; combination therapy; heart failure; renal outcomes.

Copyright © 2025 Aristizábal-Colorado, Corredor-Rengifo, Sierra-Castillo, López-Corredor, Vernaza-Trujillo, Weir-Restrepo, Izquierdo-Condoy, Ortiz-Prado, Rico-Fontalvo, Gómez-Mesa, Abreu-Lomba and Rivera-Martínez.

PubMed Disclaimer

Erratum for

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.
Aristizábal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, López-Corredor C, Vernaza-Trujillo DA, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gómez-Mesa JE, Abreu-Lomba A, Rivera-Martínez WA. Aristizábal-Colorado D, et al. Front Endocrinol (Lausanne). 2025 Jul 7;16:1605746. doi: 10.3389/fendo.2025.1605746. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40692593 Free PMC article. Review.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Frontiers Media SA
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review

Affiliations

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review

Authors

Affiliations

Abstract

Erratum for

Publication types

LinkOut - more resources

Full Text Sources